Re: Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-invasive Bladder Cancer (SURE-02): A Single-arm, Phase 2 Study.
Laura S Mertens
,
Jan-Jaap J Mellema
,
Srikala Sridhar
,
Michiel S van der Heijden
More about this publication
European urology
Volume
90
Issue nr.
5
Pages
527-528
Publication date
01-11-2026
Full text links
Publisher website (DOI)
10.1016/j.eururo.2026.05.022
Europe PubMed Central
42303524
Pubmed
42303524